Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 842, Issue -, Pages 345-350Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejphar.2018.11.014
Keywords
Sialidase; Neuraminidase; Sialic acid; Cancer; Desialylation; Glycocalyx
Categories
Funding
- Russian Science Foundation, Russia [18-15-00254]
- Russian Science Foundation [18-15-00254] Funding Source: Russian Science Foundation
Ask authors/readers for more resources
Sialic acid residues are frequently located at the terminal positions of glycoconjugate chains of cellular glycocalyx. Sialidases, or neuraminidases, catalyse removal of these residues thereby modulating various normal and pathological cellular activities. Recent studies have revealed the involvement of sialidases in a wide range of human disorders, including neurodegenerative disorders, cancers, infectious diseases and cardiovascular diseases. The accumulating data make sialidases an interesting potential therapeutic target. Modulating the activity of these enzymes may have beneficial effects in several pathologies. Four types of mammalian sialidases have been described: NEU1, NEU2, NEU3 and NEU4. They are encoded by different genes and characterized by different subcellular localization. In this review, we will summarize the current knowledge on the roles of different sialidases in pathological conditions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available